Mercado global de expetorantes orais – Tendências do setor e previsão para 2031

Análise e dimensão do mercado de expetorantes orais

Os casos crescentes de tosse seca que causa secura na garganta impulsionam o mercado dos expetorantes. No entanto, a fácil disponibilidade de medicamentos expetorantes OTC e o aumento da prevalência de doenças respiratórias impulsionarão o mercado dos expetorantes. Os avanços médicos que envolvem a descoberta contínua de medicamentos e as iniciativas organizacionais governamentais e não governamentais impulsionam o crescimento do mercado.

A Data Bridge Market Research analisa que o mercado global de expetorantes orais, que foi de 4.243,60 milhões de dólares em 2023, deverá atingir os 5.375,67 milhões de dólares até 2031, e deverá passar por um CAGR de 3,1% durante o período de previsão. Este indica o valor de mercado. “Droga” domina o segmento de tipo do mercado devido à crescente prevalência de doenças respiratórias. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Definição de mercado

Expectorants are the medical agents that help in clearing or bringing up mucus from the lungs, bronchi, and trachea. They act by promoting drainage of mucus from the lungs by thinning the mucus and reducing the respiratory tract's irritation by lubrication. They also help to relieve chest congestion caused by colds, allergies, and flu. 

Global Oral Expectorant Market Dynamics

Drivers

• Increased Initiatives by Government and Market Players

The increasing number of efforts and initiatives that are being initiated by the government and major market leaders all over the world are boosting market growth. Governments in many countries have launched several initiatives towards launching more and more expectorants that will help in the betterment of the patients. Thus, these factors drive the market growth.

• Rising Demand for Oral Drugs

The market is witnessing a surge in demand for oral drugs, which serves as a key driver for its growth. The rising preference for oral medications can be attributed to their convenience, ease of administration, and patient compliance. Oral drugs offer several advantages, including faster onset of action, improved bioavailability, and reduced need for invasive procedures. Moreover, the development of innovative formulations and advancements in drug delivery technologies have further fueled the demand for oral expectorants. This growing trend of oral drug consumption is expected to significantly propel the market in the future.

Opportunity

• Increased FDA Approvals

Increased FDA approvals present a significant opportunity in the market. The stringent regulatory standards and rigorous approval processes enforced by the FDA ensure the safety, efficacy, and quality of expectorant drugs. As the FDA continues to grant approvals for new expectorant formulations, it instills confidence among healthcare professionals and patients regarding their effectiveness. These approvals open avenues for pharmaceutical companies to introduce innovative products and expand their market presence. The growing number of FDA-approved expectorants enables healthcare providers to offer a broader range of treatment options, addressing various respiratory conditions. This opportunity fosters market growth and enhances patient care in the expectorants sector. 

Restraint/Challenge

• Increased Side Effects

Increased side effects pose a significant challenge in the market. While expectorants are commonly used to relieve respiratory congestion, they may also be associated with adverse effects such as dizziness, nausea, gastrointestinal disturbances, and allergic reactions. The occurrence of these side effects can impact patient compliance and overall treatment outcomes. Furthermore, severe or unexpected side effects may lead to safety concerns, resulting in regulatory scrutiny and potential market restrictions. Pharmaceutical companies need to invest in research and development to minimize side effects and improve the safety profile of expectorant drugs. Addressing this challenge is crucial to maintain patient trust and sustain the growth of the market.

Recent Development

• In March 2018, Perrigo Company plc. received FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the guaifenesin market growth during the forecast period.

Global Oral Expectorant Market Scope

The oral expectorant market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Drug
• OTC
• Herbal
• Others

Route of Administration

• Oral
• Inhalational
• Others

End-User

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Oral Expectorant Market Regional Analysis/Insights

The oral expectorants market is analyzed and market size insights and trends are provided by country, type, route of administration, distribution channel, and end-user as referenced above.     

The countries covered in the market report are the U.S., Canada, Mexico, Peru, Brazil, Argentina, rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, and rest of Middle East and Africa.      

North America is expected to dominate the market due to the strong base of healthcare facilities, the strong presence of major players in the market, increasing inclination towards respiratory medicines, and rising number of research activities in this region.        

Asia-Pacific is expected to witness significant growth during the forecast period due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the região.

A secção de países do relatório também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas, análise das cinco forças de Porter e estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e as rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.  

Base instalada de crescimento da infraestrutura de saúde e penetração de novas tecnologias

O mercado de expectorantes orais também fornece uma análise de mercado detalhada para o crescimento de cada país em termos de despesas de saúde para equipamentos de capital, base instalada de diferentes tipos de produtos para o mercado de expectorantes orais, o impacto da tecnologia utilizando curvas de salvação e alterações nos cenários regulamentares de saúde e o seu impacto no mercado dos expetorantes orais.

Cenário competitivo e análise global da quota de mercado de expetorantes orais

O panorama competitivo do mercado dos expetorantes orais fornece detalhes dos concorrentes. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produtos, largura e amplitude do produto, domínio da aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado dos expetorantes orais.

Alguns dos principais players que operam no mercado dos expetorantes orais são:

• Merck KGaA (Alemanha)
• Novartis AG (Suíça)
• (EUA)
• Johnson & Johnson Private Limited (EUA)
• Mylan NV (EUA)
• (Israel)
• Sanofi (França)
• Sun Pharmaceutical Industries Ltd. (Índia)
• Aurobindo Pharma (Índia)
• Biocon (Índia)
• Empresa Bristol-Myers Squibb (EUA)
• GSK plc (Reino Unido)
• Reckitt Benckiser Group PLC (Reino Unido)
• (EUA)

SKU-70520